 |
| |
| May-13-20 | Initiated |
H.C. Wainwright |
Buy |
$42 |
|
| Mar-04-20 | Initiated |
Barclays |
Overweight |
$40 |
|
| Jan-09-20 | Downgrade |
BMO Capital Markets |
Outperform → Market Perform |
$22 |
|
| Dec-30-19 | Reiterated |
Mizuho |
Buy |
$27 → $33 |
|
| Dec-09-19 | Upgrade |
Wells Fargo |
Market Perform → Outperform |
|
|
| Nov-12-19 | Initiated |
SunTrust |
Buy |
$25 |
|
| Nov-06-19 | Downgrade |
Wells Fargo |
Outperform → Market Perform |
|
|
| Oct-01-19 | Initiated |
Stifel |
Buy |
$27 |
|
| Aug-09-19 | Initiated |
BTIG Research |
Buy |
$27 |
|
| Jul-22-19 | Initiated |
Cantor Fitzgerald |
Overweight |
|
|
| Jul-12-19 | Initiated |
Oppenheimer |
Outperform |
$27 |
|
| Jun-13-19 | Initiated |
Mizuho |
Buy |
|
|
| Jun-07-19 | Initiated |
ROTH Capital |
Neutral |
$20 |
|
| May-31-19 | Initiated |
Guggenheim |
Buy |
|
|
| May-24-19 | Resumed |
Citigroup |
Buy |
$26 |
|
| Mar-28-19 | Initiated |
SVB Leerink |
Outperform |
$20 |
|
| Jan-03-19 | Downgrade |
Stephens |
Overweight → Equal-Weight |
|
|
| Nov-05-18 | Initiated |
Jefferies |
Buy |
|
|
| Aug-01-18 | Initiated |
Citigroup |
Buy |
$20 |
|
| Mar-06-18 | Downgrade |
H.C. Wainwright |
Buy → Neutral |
$12 |
|
|
|
| Oct-15-20 08:00AM | |
| Sep-30-20 08:00AM | |
| Sep-11-20 10:11AM | |
| Sep-04-20 08:00AM | |
| Aug-19-20 08:00AM | |
| Aug-11-20 08:19AM | |
| 08:00AM | |
| Aug-05-20 05:55PM | |
| 04:01PM | |
| Aug-04-20 04:01PM | |
| Jul-29-20 04:01PM | |
| Jul-28-20 12:32PM | |
| Jul-26-20 07:40AM | |
| Jul-21-20 08:11AM | |
| Jul-16-20 11:06AM | |
| Jul-14-20 08:00AM | |
| Jul-10-20 10:18AM | |
| Jul-09-20 08:00AM | |
| Jun-15-20 10:50PM | Thomson Reuters StreetEvents |
| 01:44PM | |
| Jun-13-20 07:50AM | |
| Jun-11-20 04:01PM | |
| Jun-09-20 05:29PM | |
| 02:10PM | |
| 12:49AM | |
| Jun-08-20 04:01PM | |
| May-20-20 08:00AM | |
| May-15-20 06:18AM | |
| May-12-20 04:30PM | |
| 01:40PM | |
| May-11-20 05:15PM | |
| 04:01PM | |
| May-08-20 08:46AM | |
| May-05-20 09:18PM | |
| 04:01PM | |
| May-04-20 04:01PM | |
| 09:38AM | |
| Apr-30-20 08:33AM | |
| Apr-29-20 07:11AM | |
| Apr-28-20 04:30PM | |
| 12:33PM | |
| Apr-14-20 09:13AM | |
| Apr-10-20 12:00PM | |
| Apr-08-20 11:30AM | |
| 10:05AM | |
| 10:04AM | |
| Apr-06-20 09:08AM | |
| Apr-04-20 09:07AM | |
| Apr-03-20 06:34PM | |
| 04:20PM | Investor's Business Daily |
| 10:57AM | |
| 07:36AM | |
| Apr-02-20 04:46PM | |
| 04:45PM | |
| Mar-25-20 09:04AM | Thomson Reuters StreetEvents |
| Mar-17-20 10:24AM | |
| Mar-02-20 05:15PM | |
| 04:01PM | |
| Feb-29-20 02:52PM | |
| Feb-26-20 08:00AM | |
| Feb-25-20 12:30PM | |
| Feb-07-20 08:00AM | |
| Feb-05-20 11:52AM | |
| Jan-16-20 06:15AM | |
| Jan-13-20 08:00AM | |
| Jan-03-20 10:44AM | |
| Dec-13-19 02:18PM | Thomson Reuters StreetEvents |
| Dec-11-19 09:41AM | |
| Dec-10-19 09:52AM | |
| 09:48AM | |
| 09:07AM | |
| Dec-09-19 04:19PM | Investor's Business Daily +41.33% |
| 02:16PM | |
| 11:04AM | |
| Dec-08-19 07:28PM | |
| 10:39AM | |
| Dec-07-19 08:40AM | |
| Dec-02-19 05:49AM | |
| Nov-27-19 04:01PM | |
| Nov-14-19 04:01PM | |
| Nov-06-19 09:01AM | |
| Nov-05-19 07:25PM | |
| 04:05PM | |
| Oct-29-19 04:01PM | |
| Oct-28-19 07:44PM | |
| Oct-18-19 08:12AM | |
| 05:57AM | |
| Oct-01-19 01:48PM | |
| Sep-30-19 08:00AM | |
| Sep-18-19 04:01PM | |
| Sep-12-19 07:38AM | |
| 12:53AM | |
| Sep-11-19 04:01PM | |
| Sep-10-19 11:06AM | |
| Sep-04-19 10:02AM | |
| Sep-03-19 08:01AM | |
| Aug-29-19 08:00AM | |
| Aug-14-19 08:00AM | |
| Aug-09-19 11:50AM | Thomson Reuters StreetEvents |
| Aug-07-19 12:20PM | |
|
|
|
|
| Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| TAHL CINDY | General Counsel and Secretary | Oct 16 | Option Exercise | 2.73 | 29,199 | 79,713 | 128,717 | Oct 20 04:01 PM | | TAHL CINDY | General Counsel and Secretary | Oct 16 | Sale | 50.25 | 29,199 | 1,467,212 | 99,518 | Oct 20 04:01 PM | | TAHL CINDY | General Counsel and Secretary | Oct 01 | Option Exercise | 2.73 | 35,000 | 95,550 | 134,518 | Oct 02 04:01 PM | | TAHL CINDY | General Counsel and Secretary | Oct 01 | Sale | 40.74 | 35,000 | 1,426,065 | 99,518 | Oct 02 04:01 PM | | Valamehr Bahram | Chief Development Officer | Sep 14 | Option Exercise | 2.75 | 25,000 | 68,778 | 112,211 | Sep 16 04:02 PM | | Shoemaker Daniel D | Chief Scientific Officer | Sep 14 | Sale | 36.30 | 25,000 | 907,540 | 118,091 | Sep 16 04:01 PM | | Valamehr Bahram | Chief Development Officer | Sep 14 | Sale | 36.28 | 25,000 | 907,024 | 87,211 | Sep 16 04:02 PM | | Redmile Group, LLC | Director | Jun 11 | Buy | 28.31 | 1,412,928 | 39,999,992 | 12,629,737 | Jun 17 08:25 PM | | RASTETTER WILLIAM H | Director | Mar 30 | Option Exercise | 1.37 | 28,461 | 38,992 | 28,461 | Mar 31 04:01 PM | | Valamehr Bahram | Chief Development Officer | Feb 03 | Option Exercise | 1.69 | 1,153 | 1,949 | 87,211 | Feb 04 04:01 PM | | Wolchko J Scott | President and CEO | Jan 30 | Option Exercise | 2.70 | 25,000 | 67,500 | 444,969 | Feb 03 04:01 PM | | Wolchko J Scott | President and CEO | Jan 30 | Sale | 25.45 | 25,000 | 636,303 | 419,969 | Feb 03 04:01 PM | | Valamehr Bahram | Chief Development Officer | Jan 08 | Sale | 20.69 | 5,700 | 117,947 | 86,058 | Jan 10 04:03 PM | | TAHL CINDY | General Counsel and Secretary | Jan 08 | Sale | 20.72 | 5,700 | 118,085 | 99,518 | Jan 10 04:02 PM | | Shoemaker Daniel D | Chief Scientific Officer | Jan 08 | Sale | 20.70 | 5,700 | 117,986 | 143,091 | Jan 10 04:01 PM | | Shoemaker Daniel D | Chief Scientific Officer | Dec 30 | Option Exercise | 2.90 | 25,000 | 72,500 | 148,791 | Jan 02 04:01 PM | | Shoemaker Daniel D | Chief Scientific Officer | Dec 30 | Sale | 19.50 | 25,000 | 487,427 | 123,791 | Jan 02 04:01 PM | | Wolchko J Scott | President and CEO | Dec 20 | Option Exercise | 2.70 | 25,000 | 67,500 | 378,969 | Dec 23 04:02 PM | | Wolchko J Scott | President and CEO | Dec 20 | Sale | 20.17 | 25,000 | 504,158 | 353,969 | Dec 23 04:02 PM | | Wolchko J Scott | President and CEO | Dec 19 | Option Exercise | 2.70 | 25,000 | 67,500 | 378,969 | Dec 23 04:02 PM | | Wolchko J Scott | President and CEO | Dec 19 | Sale | 20.08 | 25,000 | 501,898 | 353,969 | Dec 23 04:02 PM |
|
|
|
|
|
|
